
Quality and Safety in Biopharmaceutical Production
The biopharmaceutical industry is experiencing a drive towards biologic products due to their promise as treatments for chronic diseases.
The biopharmaceutical industry is experiencing a drive towards biologic products due to their promise as treatments for chronic diseases.
Andrew Badrot, CEO of C2 Pharma and a close observer of pharma industry trends, analyzes the current situation and how this pandemic may kick of changes in the pharma market.